PROVIDENCE – Rubius Therapeutics Inc. reported on Tuesday a loss of $39.4 million in the second quarter of 2019, or 50 cents per diluted share. Rubius posted operating expenses, including research and development expenditures, of $41.3 million. The Cambridge, Mass.-headquartered company, which specializes in allogenic cellular therapies for several diseases and across multiple therapeutic areas,…
Want More Free?
To access 2 more articles, please log in or register for free.
Registered users get access to a limited number of free articles every month.